Business Context and Reporting Period
This Form 8-K was filed by Pavmed Inc. on June 6, 2023, reporting events occurring on May 31, 2023. The company is a Delaware corporation developing the Veris Health implantable physiologic monitor, designed to track key physiologic parameters to predict adverse outcomes in cancer patients undergoing treatment.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, or debt metrics. The specific financial transaction reported is as follows:
- Transaction Value: $750,000 non-refundable advance payment.
- Payment Method: Issuance of 1,500,000 shares of common stock to Sunrise Labs, Inc.
- Counterparty: Sunrise Labs, Inc. (accredited investor).
- Regulatory Status: Unregistered sale of equity securities under Section 4(a)(2) of the Securities Act.
Material Changes and Transaction Details
The primary material change is the agreement to issue equity in lieu of cash to fund product development. Key terms include:
- Valuation Adjustment: On the six-month anniversary, the market value of the shares will be calculated based on the volume-weighted average price of the last ten trading days.
- Shortfall Remedy: If the aggregate value is less than $750,000, Pavmed may pay the difference in cash or issue additional shares (calculated using the greater of the current value or $0.10 per share).
- Ownership Cap: The total number of shares issued to Sunrise will not exceed 9.99% of the company's outstanding common stock as of May 31, 2023.
Management Commentary and Strategic Outlook
Management states that this arrangement is intended to assist the company in meeting its development timeline for the Veris Health monitor while preserving cash reserves. By utilizing equity compensation, the company aims to continue the development of electronics and firmware without immediate cash outflow.
Investor Verification Checklist
- Verify the current volume-weighted average price of PAVM stock to assess potential future dilution if a valuation shortfall occurs.
- Confirm the total outstanding share count as of May 31, 2023, to calculate the exact percentage ownership Sunrise Labs will hold.
- Review the development timeline for the Veris Health implantable physiologic monitor to gauge the urgency of the funding.
- Check subsequent filings for any cash payments or additional share issuances related to the six-month valuation adjustment.